Related references
Note: Only part of the references are listed.Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Fang-Hui Zhao et al.
LANCET INFECTIOUS DISEASES (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis
Aikaterini Tsentemeidou et al.
SEXUALLY TRANSMITTED DISEASES (2021)
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Epidemiologic Profile of Type-Specific Human Papillomavirus Infection after Initiation of HPV Vaccination
Masayuki Sekine et al.
VACCINES (2020)
Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-TypeSpecific Effectiveness and Evidence of Cross-Protection
Risa Kudo et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study
Hiroshige Mikamo et al.
VACCINE (2019)
Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up
Lihui Wei et al.
VACCINE (2019)
Evaluation of future cervical cancer risk in Japan, based on birth year
Asami Yagi et al.
VACCINE (2019)
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
Feng-Cai Zhu et al.
CANCER MEDICINE (2019)
Dynamic changes in Japan's prevalence of abnormal findings in cervical cervical cytology depending on birth year
Yutaka Ueda et al.
SCIENTIFIC REPORTS (2018)
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25years: event-triggered analysis of a randomized controlled trial
Feng-cai Zhu et al.
CANCER MEDICINE (2017)
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis
Didik Setiawan et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations
VACCINE (2017)
Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery
Anna W. LaVigne et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Melanie Drolet et al.
LANCET INFECTIOUS DISEASES (2015)
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial
Ting Wu et al.
VACCINE (2015)
Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10-to 14-year-old Girls Open 6-year Follow-up of an Initial Observer-blinded, Randomized Trial
Tino F. Schwarz et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2014)
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women Open follow-up of a randomized clinical trial up to 4 years post-vaccination
Ryo Konno et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
Mark H. Einstein et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Impact of HPV16/18 vaccination on quality of life: A pilot study
Tiina Eriksson et al.
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE (2013)
Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10-25-Year-Old HIV-Seronegative African Girls and Young Women
Papa Salif Sow et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females
Rongcheng Li et al.
VACCINE (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years
Ryo Konno et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
Joakim Dillner et al.
BRITISH MEDICAL JOURNAL (2010)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
Nubia Munoz et al.
LANCET (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
Cosette M. Wheeler et al.
VACCINE (2008)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
Gonzalo Perez et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
Stan L. Block et al.
PEDIATRICS (2006)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
